ArticleFrontiers in oncology2025
Prognostic alternative mRNA splicing in lung adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alternative splicing (AS) of mRNA has emerged as a promising biomarker for various tumors, playing a crucial role throughout nearly all stages of tumor progression and influencing the tumor immune microenvironment (TIME). Our study was designed to develop an AS-based signature for accurate prognosis prediction in lung adenocarcinoma (LUAD) patients, to delineate the associated immune cell landscape, and to pinpoint promising drug targets. Methods: Prognostic alternative splicing events (PASEs) were identified through univariate Cox regression analysis of RNA-Seq data from The Cancer Genome Atlas (TCGA). These PASEs were incorporated into a least absolute shrinkage and selection operator-Cox proportional hazards model to develop a prognostic signature. Experimental validation was performed using reverse transcription quantitative polymerase chain reaction, immunohistochemistry, and functional assays Results: A total of 13 PASEs were selected to form the prognostic signature, which demonstrated excellent predictive power for 1-, 2-, and 3-year overall survival (OS), with area under the receiver operating characteristic curve values of 0.776, 0.751, and 0.767, respectively. High-risk patients, identified by the signature, showed significantly decreased stromal, immune, and combined scores; increased tumor purity ( Conclusion: PASEs constitute a comprehensive biomarker for predicting prognosis and monitoring the TIME in LUAD patients. Specifically, CDKN2A stands out as a potential prognostic biomarker and drug target for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.